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Abstract
Background: There is a high prevalence of diabetes mellitus (DM) and dyslipidemia in women with polycystic
ovary syndrome (PCOS). The purpose of this study was to investigate the role of different metabolic pathways in
the development of diabetes mellitus in high-androgen female mice fed with a high-fat diet.
Methods: Female Sprague-Dawley rats were divided into 3 groups: the control group(C), n = 10; the andronate-
treated group (Andronate), n = 10 (treated with andronate, 1 mg/100 g body weight/day for 8 weeks); and the
andronate-treated and high-fat diet group (Andronate+HFD), n = 10. The rate of glucose appearance (Ra of
glucose), gluconeogenesis (GNG), and the rate of glycerol appearance (Ra of glycerol) were assessed with a stable
isotope tracer. The serum sex hormone levels, insulin levels, glucose concentration, and the lipid profile were also
measured.
Results: Compared with control group, both andronate-treated groups exhibited obesity with higher insulin
concentrations (P < 0.05) but similar blood glucose concentrations. Of the two andronate-treated groups, the
andronate+HFD group had the most serious insulin resistance (IR). Estrus cycles were completely acyclic, with
polycystic ovaries and elevated serum lipid profiles in the andronate+HFD group (P < 0.05). Ra of glucose and GNG
increased significantly in the andronate+HFD rats. However, the Ra of glycerol was similar in the three groups.
Conclusions: Andronate with HFD rat model showed ovarian and metabolic features of PCOS, significant increase
in glucose Ra, GNG, and lipid profiles, as well as normal blood glucose levels. Therefore, aberrant IR, increased
glucose Ra, GNG, and lipid metabolism may represent the early-stage of glucose and lipid kinetics disorder, thereby
might be used as potential early-stage treatment targets for PCOS.
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Background
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in women of reproductive
age [1] and is the most frequent cause of hyperandro-
genism and anovulation [2]. PCOS is also strongly asso-
ciated with abdominal obesity, hyperinsulinemia, insulin
resistance, and type 2 diabetes [3]. The pathophysiology
of PCOS is largely unknown but has been attributed to
defects in various organ systems. Uncontrolled ovarian
steroidogenesis with a thickened thecal layer that secrets
excessive androgen is thought to be a primary abnorm-
ality of PCOS [4]. PCOS is combined with defects in
insulin action and insulin resistance (IR) finally leading
to diabetes, and it also displays neuroendocrine dysfunc-
tion with exaggerated LH pulsatility, and altered produc-
tion of adrenal androgen [5].
Once a diagnosis of PCOS is confirmed, it is impera-
tive to assess the woman for diabetes mellitus (DM) risk
factors. Despite the many reasons that women seek
medical care for PCOS, the greatest long-term risk for
these women is DM [6]. The link between PCOS and
DM is multi-faceted [7]. Insulin resistance (IR) is
increased in age-matched PCOS women and is linked to
hyperandrogenism [8]. No single blood test is available
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sensus recommendation for the assessment of DM risk
factors exists, measurement of glucose metabolism, lipid
screening, and measurements of insulin concentrations
have been suggested [9].
Due to the heterogeneity of PCOS, it is difficult to
create a single animal model that expresses the main
PCOS characteristics [10]. We used andronate (testos-
terone propionate), a steroid hormone of the androgen
group, in combination with high-fat diet (HFD) to estab-
lish a rat model of PCOS. The aim of this study was to
investigate the metabolic pathways in glucose metabo-
lism, lipid production, and gluconeogenesis with a stable
tracer method. This method allows noninvasive detec-
tion of key steps in glucose and lipid metabolism, lead-
ing to the understanding of the mechanisms by which
PCOS modifies glucose and lipid metabolism and treat-
ment targets for PCOS.
Methods
Animals and experiment design
Female Sprague-Dawley rats (3 weeks old) were bred
and housed locally at 22°C ± 2°C under a 12 h on, 12 h
off light cycle with free access to food and water. The
rats were randomly divided into three groups for the
next 8 weeks of treatment. The protocol of the study is
presented in Figure 1.
Control group (n = 10): The rats were fed with a stan-
dard laboratory diet (52% carbohydrate, 22.1% protein,
9.2% water, 5.28% fat, 4.12% cellulose, 4.22% mineral
salts) and were injected with olive oil of a similar
volume as the experimental group.
Andronate group (n = 10): The rats were injected with
andronate subcutaneously at a dose of 1 mg/100 g body
weight/day for 8 weeks. The rats were also fed with a
standard laboratory diet.
Andronate combined high-fat diet group (n = 10): The
rats were injected with andronate subcutaneously at a
dose of 1 mg/100 g body weight/day for 8 weeks. The
rats were also fed with a lipid-enriched diet (54.2% stan-
dard diet, 16.8% lard, 15% sucrose, 9% casein, 1% miner-
als, 1% vitamins, 3% malt dextrin).
Body weight and blood glucose were measured weekly.
All the animal procedures were performed in accor-
dance with the ethical principles in animal research
adopted by the Department of Laboratory Animal
Science, Jiaotong University School of Medicine, Shang-
hai, China.
Vaginal smears
A moistened cotton bud swab was gently inserted into
the vagina. The cells were removed from the vaginal
lumen and walls and then transferred onto a glass slide.
It is the quickest way of smearing and the smears retain
their original appearance indefinitely. The stage of cycli-
city was determined by microscopic analysis of the pre-
dominant cell types in vaginal smears. The vaginal
smears were analyzed daily since 8 weeks of age to the
end of the experiment.
Ovarian morphology
Ovarian tissue from each group was fixed in 4% parafor-
maldehyde, dehydrated with ethanol and xylene,
embedded in paraffin, and sliced into 5-μm sections on
a microtome (SLEE, Germany). The sections were
stained with hematoxylin-eosin (HE) and analyzed
under an optical microscope (CKX41, Olympus, Japan).
Blood sample collection and assays
One week prior to the treatment, tail blood was
obtained after an overnight fast to assess the glucose,
insulin, and sex steroid levels and the lipid profile.
Plasma glucose and lipids concentration were assayed by
Siemens Dimension MAX (Siemens Healthcare Diagnos-
tics Inc). Plasma insulin was assayed by magnetic affinity
immunoassay (Insulin MPAIA Kit). Sex steroids,
Figure 1 Research protocol of the experiment. The rats were divided into three groups. The arrows indicate the times of blood draws and
isotope infusion. A vaginal smear was administrated everyday since 8 weeks.
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hormone (LH), and testosterone (T) were assayed by
chemiluminescent microparticle immunoassay (CMIA).
Stable isotope infusion procedure
At 11 weeks of age, the tail-artery was catheterized for
blood collection after an overnight fast. During the pro-
cedure, only the tail was anesthetized locally with lido-
caine. The procedure took 15 min to complete. This
catheterization allowed frequent collection of arterial
blood samples while tracers were infused intravenously,
as well as the adherence to the optimal V-A mode of
metabolic experiments. The animals were relaxed with
the ability to move partially, groom and drink. Thus,
experimental stress was minimized. When blood glucose
returned to baseline (usually within 30 min) shown by a
hand-held glucose device (Terumo, medisafe mini blood
glucose reader, manufactured by: Terumo corporation,
Tokyo, Japan), a flexible plastic intravenous infusion line
was placed in the lateral tail vein by venipuncture, and
isotopic tracer infusions were commenced as described
below. The experimental setting is shown in Figure 2.
In vivo experiments
In this study, appearance of glucose and glycerol were
traced by [6,6-2D]-glucose and [U-13 C]-glycerol, while
gluconeogenesis (GNG) were accessed by [1,2,3-13 C]-glu-
cose and [U-13 C]-glycerol, [6,6-2D]-glucose (2 μmol/kg/
min) and [U-13 C]-glycerol (0.84 μmol/kg/min) were
infused intravenously constantly, without priming, through
the tail infusion line driven by an infusion pump (Harvard
Apparatus, Holliston, MA, USA)for 90 min. This is
defined as the basal period. During the last 10 min (80-90
min), arterial blood samples (0.5 ml each) were collected 5
min intervals from the tail arterial catheter. These samples
were used for the quantitation of steady state glucose and
glycerol metabolism. The rats were then euthanized by
heart-opening under anesthesia with pentobarbital (50
mg/kg) in order to reduce blood elements in tissues. Ovar-
ies were harvested swiftly. Plasma was prepared on site
and saved at -80°C for later analysis. A flow chart of the
study design is shown in Figure 3.
Gas chromatography/mass spectrometry
Plasma samples from the infusion experiments were pro-
cessed chromatographically by methoxyamine-HCl and
BSTFA to get m/z: 321/319 [6,6-2D]-glucose, and m/z:
221/218 [U-13 C]-glycerol. To exclude the interference of
spill over from the [6,6-2D]-glucose to [1,2,3-13 C]-glu-
cose (formed in gluconeogenesis whose precursor is [U-13
C]-glycerol), hydroxylamine hydrochloride was used to
derivation. Then the derivation was analyzed by gas chro-
matography/mass spectrometry (autoSystem XL GC/Tur-
b o M a s sM S )f o rt h ee n r i c h m e n t .T h eG Co v e n
temperature was programmed initially at 70°C for 4 min,
increased to 240°C at 10°C/min, then to 300°C at 20°C/
Figure 2 Experimental setting for stable isotope infusion. The rats catheterized in the tail artery for blood collection and in the tail vein for
isotope infusion. The rats were relaxed, with the ability to move partially, groom and drink. Thus, experimental stress was minimized.
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nically controlled for constant pressure and humidity.
Calculation of glycerol and glucose appearance rates and
rates of gluconeogenesis
T h ei n f u s i o nr a t e( μmol/kg/min) of [U-13 C]-glycerol
and [6,6-2D]-glucose was divided by mole percent
excess (MPE) of plasma glycerol and that of glucose,
respectively, to give the appearance rates (μmol/kg/min).
Gluconeogenesis rates were calculated by dividing the
MPE of plasma [U-13 C]-glycerol by the MPE of [1,2,3-
13 C]-glucose. In this experiment, appreciable amounts
of [U-13 C]-glycerol were converted to [1,2,3-13 C]-glu-
cose via gluconeogenesis. Thus gluconeogenesis rates
can be compared among different groups.
Statistical analysis
The data were expressed as mean ± standard deviation
(SD), unless otherwise indicated. Statistical significance
was tested by analysis of variance (ANOVA). A value of
P< 0.05 was considered significant.
Results
Body weight and blood glucose curves
Andronate-treated two groups exhibited a significant
increase in the mean body weight at the end of the
study (andronate group: 244.5 ± 11.5, andronate + HFD
group: 253.8 ± 19.7; vs. control group: 214.7 ± 13.0, P <
0.05) (Figure 4A). However, there was no significant dif-
ference in blood glucose levels between the three groups
over the 8 weeks time course (Figure 4B).
Reproductive cycles of rats
Reproductive cycles were assessed by vaginal smears.
The control group exhibited regular estrous cycles (Fig-
ure 5), whereas the two experimental groups had pro-
longed or irregular estrous cycles, most of which
showed a constant diestrus smear (Figure 5C).
Ovarian morphology
Light microscope revealed normal ovarian structures in
the control group (Figure 6A, D), with follicles and
corpora lutea in various stages and no ovary cysts were
observed. The ovaries of the andronate-treated group
were much smaller than those of the control group (Fig-
ure 6B), with many cystic follicles with apoptotic granu-
losa cells (Figure 6E). The andronate + HFD group had
larger ovaries than the control group, with a fatty infil-
tration surrounded the ovaries (Figure 6C). In addition,
cystic follicles with macrophages and fluid were also
observed (Figure 6F). In general, both experimental
groups had fewer corpus lutea and preovulatory follicles
and had more preantral and antral follicles than the
controls.
Body hair changes
After 8 weeks treatment with andronate and diet chan-
ging, the two treated groups showed hirsutism and
longer body hair, while the control group had no unu-
sual body hair changes (Figure 7).
Fasting blood glucose (FBG) levels, fasting plasma insulin
(FINS) levels, homeostasis model-insulin resistance
(HOMA-IR), and insulin sensitivity index (ISI)
The FBG levels were similar among all the three groups,
approximately 5 mmol/L. The FINS concentrations were
10.0 ± 1.1 mU/L (control), 15.9 ± 2.1 mU/L (andronate),
and 20.3 ± 1.8 mU/L (andronate and HF), respectively.
T h eH O M A - I Ri nt h ea n d r o n a t e+H F Dg r o u pw a s
markedly elevated (4.43 ± 0.45), while was mildly ele-
vated in the andronate group (3.49 ± 0.49) compared to
the control group (2.14 ± 0.21). The insulin sensitivity
index was inverse, as both the andronate + HFD and
the andronate groups had a lower insulin sensitivity
index (-4.6 ± 0.10 and -4.35 ± 0.15, respectively) than
the control group (-3.87 ± 0.10, P< 0.05) (Figure 8).
Profiles of serum hormone levels
Although FSH levels were not affected, the LH levels
were increased in the andronate-treated groups. Conse-
quently, the LH/FSH ratio was elevated in the treated
group, mirroring the changes observed in human PCOS.
Furthermore, testosterone levels were significantly aug-
mented in the andronate + HFD group, indicating that
Figure 3 Protocol of in vivo infusions of stable isotopes. This is the protocol of steady-state isotope infusion. The arrows indicate the times
for blood draws and tissue sampling.
Zhai et al. Reproductive Biology and Endocrinology 2012, 10:5
http://www.rbej.com/content/10/1/5
Page 4 of 9Figure 4 Body weight and blood glucose levels in three groups. Since 3 weeks of age, body weight measurements and blood glucose
levels were taken every week. A: body weight changes in the 3 groups; B: blood glucose levels in the 3 groups.
Figure 5 The main stages of the reproductive cycle in the control rats. Swab smears (unstained) shown with the original microscope
magnification of 100×. A:Estrus stage: large cornified cells in clumps. B: Metestrus stage: large numbers of leucocytes with smaller numbers of
non-nucleated epithelial cells (note characteristic clumping together of two cell types at the center-right). C: Diestrus stage: predominantly
leucocytes with a small number of epithelial and cornified cells. D: Proestrus stage:epithelial cells are mostly rounded but some cells shows early
stages of cornification of approaching estrus.
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(Table 1).
Plasma lipid profile
Disturbances in the plasma lipid profiles were appar-
ent (Table 2). There were increases in plasma concen-
trations of TC (total cholesterol), TG (triglycerides),
and LDL-C (high density lipoprotein-cholesterol) in
andronate-treated rats, and the plasma concentrations
of these molecules were further elevated in the andro-
nate + HFD group. Plasma HDL-C (high density lipo-
protein -cholesterol) levels also tended to be elevated
in the two groups, but the difference was not
significant.
Rates of glucose appearance (glucose Ra),
gluconeogenesis (GNG), rates of glycerol appearance
(glycerol Ra)
The glucose Ra was significantly increased in the andro-
nate-treated groups, while that of glycerol was not
affected. Fractional gluconeogenesis was most elevated
in the andronate + HFD group, indicating that the com-
bination of andronate and high-fat diet can increase
body glucose by accelerating gluconeogenesis from gly-
cerol (Table 3).
Discussion
Metabolism Syndrome (MS) is estimated to affect
approximately 40% of women with PCOS, leading to
Figure 6 Histology of ovaries. Ovaries were stained by HE staining:A:control group(HE staining, ×40); B:andronate group(×40); C:andronate +
HFD group(×40); D:control group(×200); E:andronate group(×200); F:andronate + HFD group(×200).
Figure 7 Body hair in the three rats groups. At 10 weeks of age, pictures were taken of the 3 groups. A:control group; B:andronate group; C:
andronate with HFD group.
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abnormal glucose metabolism [11]. We here demon-
strate that andronate with HFD rats replicate both the
ovarian and the metabolic syndrome features of human
PCOS, including PCO morphology, irregular cycles,
increased body weight, hyperlipidemia, and insulin
resistance.
It has been suggested that adolescent obesity is corre-
lated with insulin resistance (IR), dyslipidemia, and
PCOS related ovulatory dysfunction [12]. In the present
study, obesity was observed in andronate-treated groups;
however, there was no significant difference between the
groups fed with normal or high-fat diets. These results
were consistant to our previous study of castrated male
rats [13], and is likely due to failed adaptation to HFD.
Up to 70% of women with PCOS are also insulin
resistant (IR), and the prevalence of DM in women with
PCOS is 10% [14]. IR is a state of impaired metabolic
response to insulin as characterized by the American
Diabetes Association (ADA) [15]. The probable mechan-
isms of insulin-related reproductive abnormalities
include excessive LH secretion, abnormalities of ovarian
steroidogenesis, and abnormal glucose uptake in PCOS
[16]. Although some women with PCOS initially exhibit
normal glucose metabolism, the conversion rate of
abnormal glucose metabolism in 3 years is 25% [17].
This study describes an apparent insulin resistance
with increased HOMA-IR and decreased ISI in the
andronate-treated group fed with HFD, though blood
glucose (BG) of the three groups remains within normal
range. Therefore, although the glucose metabolism
abnormalities did not affect the blood glucose levels, the
potential insulin resistance might have already existed.
Thus, blood glucose level alone can not predict meta-
bolic risk in PCOS, and the precursor states of insulin
Figure 8 FBG, FINS, HOMA-IR and ISI in the 3 groups. Tail blood was obtained after an overnight fast in 10-week-old rats to assess fasting
blood glucose (FBG), fasting plasma insulin (FINS), homeostasis model-insulin resistance (HOMA-IR) and insulin sensitivity index(ISI) in 3 groups.
Table 1 FSH, LH, LH/FSH and T of andronate treated and
control groups
Group Control Andronate Andronate+high-fat
diet
FSH(mIU/
ml)
0.018 ±
0.0075
0.017 ± 0.0082 0.017 ± 0.0052
LH(mIU/ml) 0.045 ±
0.0014
0.058 ±
0.0021
a
0.053 ± 0.016
a
LH/FSH 2.61 ± 0.61 3.75 ± 1.17
a 3.25 ± 0.52
a
T(ng/ml) 2.37 ± 0.23 14.33 ± 0.92
b 16.35 ± 1.55
b
Values expressed as mean ± SD, a: p < 0.05, b: p < 0.01
Table 2 TG, TC, HDL-C and LDL-C of andronate treated
and control groups
Group Control Andronate Andronate +high-fat
TG(mmol/L) 0.80 ± 0.11 1.06 ± 0.13
a 1.24 ± 0.17
b
TC(mmol/L) 1.51 ± 0.15 1.88 ± 0.15
a 2.32 ± 0.16
b
HDL-C(mmol/L) 0.56 ± 0.10 0.57 ± 0.09 0.61 ± 0.10
LDL-C(mmol/L) 0.46 ± 0.10 0.50 ± 0.09 0.62 ± 0.05
a
Values expressed as mean ± SD, a: p < 0.05, b: p < 0.01
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BG abnormalities arise [18].
The abnormalities of glucose and lipid metabolism
were evaluated with stable isotopes. The results sug-
gested a higher rate of glucose appearance (Ra of glu-
cose) and gluconeogenesis (GNG) in andronate + HFD
rats; though the rate of glycerol appearance (Ra of gly-
cerol) showed no differences between the three groups.
Ra of glycerol provides a good measurement of whole-
body lipolysis during fasting. Because triacylglycerol is
broken down into glycerol and three fatty acids, the
amount of fatty acids released into circulation is three
times the rate of glycerol production. Therefore,
although this study showed no significant difference in
the Ra of glycerol among the three groups, the lipid pro-
files change significantly in the andronate-treated goups.
The increased Ra of glucose and GNG in combination
with the unaffected BG indicate that the dynamics of
glucose metabolism have been actively initiated in the
early state, which maybe compensated increased to
antagonist the elevated plasma insulin.
For the past several years, a number of PCOS rat
models have been used to study the etiology and patho-
physiology of PCOS. However, all of these methods
have their limitations. As PCOS can be induced with
estradiol valerate, it has been found that estradiol vale-
rate results in acyclicity and PCOS-like ovarian mor-
phology but does not cause the typical metabolic
disturbances of human PCOS [19]. In another promising
rat model, PCOS is induced by letrozole, an aromatase
inhibitor that blocks the conversion of testosterone to
estradial. While this model exhibits morphological simi-
larities to human PCOS, it does not decrease insulin
sensitivity despite increased testosterone concentrations
[20]. After continuous exposure to dihydrotestosterone
(DHT), rats develop PCOS characteristics, including
increased number of apoptotic follicles, obesity, and
insulin resistance. Thus, the DHT model is generally
preferable for studies of both ovarian and metabolic fea-
tures. However, in this model, the concentration of tes-
tosterone is low, and the mechanism of the endogenous
production of androgens or testosterone is likely to be
reduced by DHT treatment [21]. It has been strongly
suggested that high-fat diet can induce liver insulin
resistance [22] and that rats fed with HFD for 6 weeks
are notably hyperinsulinemia. Therefore, andronate
combined with high-fat diet to establish a rat model
that manifests increased similarities in the ovary and
metabolic features of PCOS.
The relationship between hyperandrogenism and IR is
significant [23]. Many human research studies have
demonstrated the high degree of this correlation [24].
Furthermore, the risk of metabolic syndrome in females
with PCOS is highly correlated with increased testoster-
one concentrations [25]. A recent review demonstrated
that women with elevated T concentrations have a
higher risk of developing type 2 diabetes mellitus [26].
Animal model have also shown that prenatal testoster-
one exposure can induce IR in early postnatal life [27],
which was confirmed in the present study.
Conclusions
A rat model of PCOS was successfully established with
features of polycystic ovaries, obesity, irregular cycles of
vaginal smear, increased plasma insulin levels, decreased
insulin sensitivity, hyperandrogenism, and increased LH
concentrations. This animal model also exhibited signifi-
cant increase in glucose Ra, rates of GNG, and lipid
profiles despite having normal blood glucose levels.
Therefore, we propose that IR, glucose Ra, GNG rates
and lipid metabolism may be potential treatment targets
for early-stage PCOS. Further studies are needed to
evaluate the effects of these treatments on PCOS and to
elucidate the complexity of PCOS etiology and
pathophysiology.
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